TOGA analysis of gene expression to accelerate target development.
With the availability of new technologies for analysis of gene expression, drug targets may now be identified through more focused rational approaches. We have developed an extremely sensitive, reproducible, and accurate method called TOGA, enabling analysis of nearly all genes within an RNA sample. This technology can be used to identify genes regulated in a great variety of situations. For example, we have been able to find genes with expression restricted to specific brain regions, and in a recent example, we found a gene regulated in specific brain regions in response to clozapine treatment. These studies will quickly lead to identification of genes critical to specific biological and clinical processes, accelerating the development of new targets and therapies.
Lo
D
D
Department of Integrative Biology, Digital Gene Technologies, Inc., 11149 North Torrey Pines Road, La Jolla, CA 92037, USA. davidlo@dgt.com
Hilbush
B
B
Sutcliffe
J G
JG
D000818:Animals; D001053:Apolipoproteins / Q000032:analysis; D053399:Apolipoproteins D; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002352:Carrier Proteins / Q000032:analysis; D003024:Clozapine / Q000494:pharmacology; D020224:Expressed Sequence Tags; D020869:Gene Expression Profiling / Q000379:methods*; D018390:Gene Targeting; D047908:Intracellular Signaling Peptides and Proteins; D051379:Mice; D009479:Neuropeptides / Q000032:analysis; D000068797:Orexins; D011333:Pro-Opiomelanocortin / Q000032:analysis; D011498:Protein Precursors / Q000032:analysis; D012984:Software
D001053:Apolipoproteins; D053399:Apolipoproteins D; D002352:Carrier Proteins; D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D000068797:Orexins; D011498:Protein Precursors; D011333:Pro-Opiomelanocortin; D003024:Clozapine